These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24187485)

  • 21. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.
    Lebedeva G; Sorokin A; Faratian D; Mullen P; Goltsov A; Langdon SP; Harrison DJ; Goryanin I
    Eur J Pharm Sci; 2012 Jul; 46(4):244-58. PubMed ID: 22085636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance.
    Gao Y; Shen JK; Milane L; Hornicek FJ; Amiji MM; Duan Z
    Curr Med Chem; 2015; 22(11):1335-47. PubMed ID: 25666804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomics-based anticancer drug discovery and development.
    Jain KK
    Technol Cancer Res Treat; 2002 Aug; 1(4):231-6. PubMed ID: 12625781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 14-3-3 zeta as novel molecular target for cancer therapy.
    Matta A; Siu KW; Ralhan R
    Expert Opin Ther Targets; 2012 May; 16(5):515-23. PubMed ID: 22512284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling.
    Alaoui-Jamali MA; Dupré I; Qiang H
    Drug Resist Updat; 2004; 7(4-5):245-55. PubMed ID: 15533762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-cancer drug development: computational strategies to identify and target proteins involved in cancer metabolism.
    Mak L; Liggi S; Tan L; Kusonmano K; Rollinger JM; Koutsoukas A; Glen RC; Kirchmair J
    Curr Pharm Des; 2013; 19(4):532-77. PubMed ID: 23016852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Big data' approaches for novel anti-cancer drug discovery.
    Benstead-Hume G; Wooller SK; Pearl FMG
    Expert Opin Drug Discov; 2017 Jun; 12(6):599-609. PubMed ID: 28462602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Searching for synthetic lethality in cancer.
    Brough R; Frankum JR; Costa-Cabral S; Lord CJ; Ashworth A
    Curr Opin Genet Dev; 2011 Feb; 21(1):34-41. PubMed ID: 21255997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomics and biomarkers in clinical trials for drug development.
    Lee JM; Han JJ; Altwerger G; Kohn EC
    J Proteomics; 2011 Nov; 74(12):2632-41. PubMed ID: 21570499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer stem cell targeting: are we there yet?
    Jung Y; Kim WY
    Arch Pharm Res; 2015 Mar; 38(3):414-22. PubMed ID: 25666873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.
    Poornima P; Kumar JD; Zhao Q; Blunder M; Efferth T
    Pharmacol Res; 2016 Sep; 111():290-302. PubMed ID: 27329331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor Metallodrugs that Target Proteins.
    Sullivan MP; Holtkamp HU; Hartinger CG
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
    Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
    Li XH; Li C; Xiao ZQ
    J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
    Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
    Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development.
    Choy G; Liu JW; Chandra D; Tang DG
    Prog Drug Res; 2005; 63():115-45. PubMed ID: 16265879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.